215. Tetralogy of Fallot
[
14 clinical trials,
16 drugs（DrugBank:
13 drugs),
13 target genes / 39 target pathways ]
Searched query = "Tetralogy of Fallot", "Fallot tetralogy"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900025513 | 2019-09-01 | 2 September 2019 | The safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary study | The safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary study | tetralogy of fallot (pulmonary atresia) | 01:N/A ;02:Oral coenzyme Q10, 2.5mg, t.i.d.;03:Oral coenzyme Q10, 5mg, t.i.d.;04:Oral coenzyme Q10, 10mg, t.i.d.;05:Oral coenzyme Q10, 20mg, t.i.d.; | Fuwai Central China Cardiovascualr Hospital | Not Recruiting | 0 | 2 | Both | 01:8;02:8;03:8;04:8;05:8; | Phase 0 | China | |
| 2 | NCT04017975 | August 2019 | 22 July 2019 | Optical Tissue Identification for Myocardial Architecture | Optical Tissue Identification for Myocardial Architecture (OPTIMA Study) | Ventricular Septal Defect;Complete Atrioventricular Canal;Tetralogy of Fallot With Pulmonary Stenosis | Drug: Fluorescite;Device: Cellvizio 100 Series System with Confocal Miniprobes | Aditya Kaza | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | 18 Years | All | 70 | Phase 2 | United States |
| 3 | ChiCTR1800019578 | 2018-12-01 | 19 November 2018 | Effects of different tranexamic acid regimen in cyanotic pediatric cardiac surgery | Effects of different tranexamic acid regimen in cyanotic pediatric cardiac surgery | Tetralogy of Fallot | Conventional treatment group:Childen did not receive an antifibrinolytic agent during surgery;Low dose of tranexamic acid group:Loading dose: 10mg/kg (infant), 5mg/kg (children); Infusion: 2mg/kg.h; CPB prime dose: 20ug/mL of prime volume;High dose of tranexamic acid group:Loading dose: 30mg/kg (infant), 15mg/kg (children); Infusion: 6mg/kg.h; CPB prime dose: 60ug/mL of prime volume; | National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Not Recruiting | Both | Conventional treatment group:225;Low dose of tranexamic acid group:225;High dose of tranexamic acid group:225; | Other | China | |||
| 4 | ChiCTR-IOR-16008571 | 2016-06-06 | 18 April 2017 | Premedication for children with Tetralogy of Fallot | A comparative evalution of varies premedication regimes on children with Tetralogy of Fallot | Tetralogy of Fallot | oral dexmedetomidine:oral dexmedetomidine;oral ketamine:oral ketamine;oral dexmedetomidine mixed with ketamine:oral dexmedetomidine mixed with ketamine; | Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University | Recruiting | Both | oral dexmedetomidine:20;oral ketamine:20;oral dexmedetomidine mixed with ketamine:20; | Other | China | |||
| 5 | EUCTR2013-002091-41-NL | 09/10/2014 | 27 October 2014 | Research into the effect of the drug losartan in adult patients with a reduced function of the right cardiac chamber and a cardiac birth defect | Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system - Redefine trial | To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Losartan Product Name: Losartan Pharmaceutical Form: Capsule, hard INN or Proposed INN: Losartan Potassium CAS Number: 124750-99-8 Current Sponsor code: losartan Other descriptive name: LOSARTAN POTASSIUM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Academisch medisch centrum | Authorised | Female: yes Male: yes | Netherlands | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01915277 | April 2, 2014 | 11 June 2018 | A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics | A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics | Transposition of the Great Arteries;Tetralogy of Fallot;Ventricular Septal Defect | Drug: Dexmedetomidine | New England Research Institutes | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | 180 Days | All | 119 | Phase 1 | United States |
| 7 | NCT02010905 | December 2013 | 4 January 2016 | Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System | Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System | Tetralogy of Fallot;Heart Defects, Congenital;Ventricular Dysfunction, Right | Drug: Losartan;Drug: Placebo | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | The Interuniversity Cardiology Institute of the Netherlands | Recruiting | 18 Years | 80 Years | Both | 120 | Phase 2 | Netherlands |
| 8 | NCT01941576 | September 2013 | 2 May 2016 | Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot | Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot | Congenital Heart Defects;Tetralogy Of Fallot | Drug: recombinant human brain natriuretic peptide (rhBNP);Drug: Placebo (0.9% sodium chloride) | Shanghai Jiao Tong University School of Medicine | Recruiting | 1 Month | 18 Years | Both | 100 | Phase 2/Phase 3 | China | |
| 9 | NCT01971593 | August 2013 | 11 June 2018 | The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease | Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease | Tetralogy of Fallot;Transposition of the Great Vessels With an Arterial Switch;Single Ventricle With a Fontan Palliation | Drug: Eplerenone | Washington University School of Medicine | Pfizer | Not recruiting | 18 Years | 80 Years | All | 26 | Phase 4 | United States |
| 10 | NCT00848393 | November 2008 | 3 August 2015 | Measures to Lower the Stress Response in Pediatric Cardiac Surgery | Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl, Low Dose Fentanyl Plus Dexmedetomidine and High Dose Fentanyl. | Tetralogy of Fallot;Ventricular Septal Defects;Atrioventricular Septal Defects | Drug: Fentanyl;Drug: Dexmedetomidine and Fentanyl | Nationwide Children's Hospital | Not recruiting | 1 Month | 3 Years | Both | 52 | N/A | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2007-003461-41-DE | 13/11/2007 | 28 August 2012 | Cardiac imaging under dobutamine stress for early assessment of right ventricular function in patients with tetralogy of Fallot and pulmonary regurgitation - Fallot-stress | Cardiac imaging under dobutamine stress for early assessment of right ventricular function in patients with tetralogy of Fallot and pulmonary regurgitation - Fallot-stress | Fallot tetralogy late after repair with marked pulmonary valve incompetence | Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Dobutamine Concentration unit: µg/kg microgram(s)/kilogram Concentration type: range Concentration number: 10-20 | Deutsche Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler | Not Recruiting | Female: yes Male: yes | 80 | Germany | ||||
| 12 | NCT00557934 | October 2007 | 19 February 2015 | Right Ventricular Contractility Reserve Following Repair of Tetralogy of Fallot | Evaluation of Right Ventricular Contractility Reserve Function During Dobutamine Stress in Patients Following Surgical Repair of Tetralogy of Fallot | Right Ventricular Dysfunction | Other: dobutamine | University Hospital Tuebingen | Fördergemeinschaft Deutsche Kinderherzzentren, Bonn, Germany | Not recruiting | 4 Years | N/A | Both | 16 | N/A | Germany |
| 13 | NCT00573066 | May 2004 | 19 October 2017 | Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery | The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery | Hypoplastic Left Heart;Tetralogy of Fallot;Tricuspid Atresia | Drug: Dexmedetomidine | Athena Zuppa | Not recruiting | 1 Month | 24 Months | All | 56 | Phase 1 | ||
| 14 | NCT00004361 | July 1995 | 19 February 2015 | Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects | Hypoparathyroidism;Tetralogy of Fallot;Pulmonary Valve Stenosis;Conotruncal Cardiac Defects;Heart Defects, Congenital;Pulmonary Atresia | Drug: calcium gluconate;Drug: sodium citrate | National Center for Research Resources (NCRR) | Ann & Robert H Lurie Children's Hospital of Chicago | Not recruiting | 18 Years | N/A | Both | 150 | N/A |